Drug reference

bamlanivimab

neutralizing mAb · SARS-CoV-2 monoclonal antibody

neutralizing mAbSARS-CoV-2 monoclonal antibody

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Bamlanivimab is a neutralizing monoclonal antibody that specifically targets the receptor binding domain (RBD) of the S protein of SARS-CoV-2.

Indications

treatment of mild to moderate COVID-19 in nonhospitalized patients with laboratory-confirmed SARS-CoV-2 infection who are at high risk for progressing to severe disease and/or hospitalization (as part of a combination with etesevimab)

Contraindications

SARS-CoV-2 antigenic variants of concern emerged that evaded its action, leading to EUA revocation

Related guidelines

Skin and soft tissue infections

IDSA · Infectious Diseases · 2010

Inflammatory bowel disease

OTHER · Gastroenterology · 2015

Coeliac disease

OTHER · Gastroenterology · 2016

Hepatitis B — chronic infection

EASL · Gastroenterology · 2025

Urinary tract infection

EAU · Urology · 2024

Ask House about bamlanivimab

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team